Benzoic acid derivatives as non nucleoside reverse transcriptase inhibitors

Abstract

Compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against HIV. In particular, the compounds are active against wild type and single or double mutant strains of HIV.

1 . A compound of the formula (I)  
     
       
         
         
             
             
         
       
     
     wherein, 
 R 1  and R 2  are each independently selected from H, halo, cyano, (C 1-4 )alkyl, (C 1-4 )haloalkyl, (C 2-4 )alkenyl, (C 2-4 )alkynyl and (C 3-6 )cycloalkyl; 
 with the proviso that when R 1  is H, R 2  cannot be H;  
 
 R 3  is halo;  
 R 4  is selected from (C 1-4 )alkyl, halo and nitro; and  
 R 5  and R 6  are each independently selected from H, halo and (C 1-4 )alkyl;  
 or a salt thereof.  
 
   
   
       2 . A compound according to  claim 1  wherein R 1  and R 2  are each independently selected from H, halo, cyano, (C 1-4 )alkyl, (C 1-4 )haloalkyl, and (C 3-6 )cycloalkyl; 
 with the proviso that when R 1  is H, R 2  cannot be H.    
   
   
       3 . A compound according to  claim 2  wherein R 1  and R 2  are each independently selected from H, fluoro, chloro, bromo, cyano, trifluoromethyl and cyclopropyl; 
 with the proviso that when R 1  is H, R 2  cannot be H.    
   
   
       4 . A compound according to  claim 1  wherein R 3  is chloro.  
   
   
       5 . A compound according to  claim 1  wherein R 4  is selected from chloro, bromo, nitro and methyl.  
   
   
       6 . A compound according to  claim 5  wherein R 4  is chloro, bromo or methyl.  
   
   
       7 . A compound according to  claim 1  wherein R 5  is H, fluoro, chloro or methyl.  
   
   
       8 . A compound according to  claim 1  wherein R 6  is H or fluoro.  
   
   
       9 . A compound according to  claim 1  wherein 
 R 1  and R 2  are each independently selected from H, halo, cyano, (C 1-4 )alkyl, (C 2-4 )alkenyl, (C 2-4 )alkynyl and (C 3-6 )cycloalkyl; wherein said (C 1-4 )alkyl is optionally substituted with one to three halo substituents; 
 with the proviso that when R 1  is H, R 2  cannot be H;  
   R 3  is halo;    R 4  is selected from (C 1-4 )alkyl, halo and nitro;    R 5  is selected from H and halo; and    R 6  is H;    or a pharmaceutically acceptable salt thereof.    
   
   
       10 . A compound according to  claim 1  wherein 
 R 1  and R 2  are each independently selected from H, halo, cyano, (C 1-4 )alkyl, (C 1-4 )haloalkyl, and (C 3-6 )cycloalkyl; 
 with the proviso that when R 1  is H, R 2  cannot be H;  
   R 3  is chloro;    R 4  is chloro, bromo, nitro or methyl;    R 5  is H, fluoro, chloro or methyl; and    R 6  is H or fluoro.    
   
   
       11 . A compound according to  claim 1  wherein 
 R 1  and R 2  are each independently selected from H, fluoro, chloro, bromo, cyano, trifluoromethyl and cyclopropyl; 
 with the proviso that when R 1  is H, R 2  cannot be H;  
   R 3  is chloro;    R 4  is chloro, bromo or methyl;    R 5  is H, fluoro, chloro or methyl; and    R 6  is H or fluoro.    
   
   
       12 . A compound of the formula  
     
       
         
         
             
             
         
       
     
     wherein R 1 , R 2 , R 4 , R 5  and R 6  are as defined in the table immediately below.  
     
       
         
               
               
               
               
               
               
               
             
                   
                   
               
                   
                   
               
                   
                 Cpd 
                 R 1   
                 R 2   
                 R 4   
                 R 5   
                 R 6   
               
                   
                   
               
                   
                 1001 
                 F 
                 CF 3   
                 Me 
                 H 
                 H; 
               
                   
                 1002 
                 F 
                 CF 3   
                 Me 
                 F 
                 H; 
               
                   
                 1003 
                 F 
                 CN 
                 Me 
                 F 
                 H; 
               
                   
                   
               
                   
                 1004 
                 F 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 Me 
                 H 
                 H; 
               
                   
                   
               
                   
                 1005 
                 F 
                 Cl 
                 Me 
                 H 
                 H; 
               
                   
                 1006 
                 H 
                 CN 
                 Me 
                 H 
                 H; 
               
                   
                 1007 
                 F 
                 CN 
                 Me 
                 H 
                 H; 
               
                   
                 1008 
                 F 
                 CF 3   
                 Cl 
                 H 
                 H; 
               
                   
                 1009 
                 F 
                 CN 
                 Cl 
                 H 
                 H; 
               
                   
                 1010 
                 F 
                 CF 3   
                 Cl 
                 F 
                 H; 
               
                   
                   
               
                   
                 1011 
                 F 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 Me 
                 F 
                 H; 
               
                   
                   
               
                   
                 1012 
                 F 
                 Br 
                 Me 
                 F 
                 H; 
               
                   
                 1013 
                 F 
                 Cl 
                 Me 
                 F 
                 H; 
               
                   
                 1014 
                 F 
                 Br 
                 Me 
                 H 
                 H; 
               
                   
                 1015 
                 H 
                 Br 
                 Me 
                 H 
                 H; 
               
                   
                 1016 
                 H 
                 Br 
                 Me 
                 F 
                 H; 
               
                   
                 1017 
                 H 
                 CN 
                 Me 
                 F 
                 H; 
               
                   
                 1018 
                 Cl 
                 CN 
                 Me 
                 H 
                 H; 
               
                   
                   
               
                   
                 1019 
                 F 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 Br 
                 H 
                 H; 
               
                   
                   
               
                   
                 1020 
                 F 
                 CF 3   
                 Br 
                 H 
                 H; 
               
                   
                 1021 
                 Cl 
                 CN 
                 Me 
                 F 
                 H; 
               
                   
                 1022 
                 F 
                 CF 3   
                 Cl 
                 Cl 
                 H; 
               
                   
                 1023 
                 F 
                 CF 3   
                 Me 
                 Me 
                 H; 
               
                   
                 1024 
                 F 
                 CF 3   
                 Me 
                 Cl 
                 H; or 
               
                   
                 1025 
                 F 
                 CF 3   
                 Me 
                 H 
                 F. 
               
                   
                   
               
                   
                   
               
           
              
              
              
              
             
             
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
             
          
         
       
     
   
   
       13 . A pharmaceutical composition, comprising a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.  
   
   
       14 . A composition according to  claim 13  additionally comprising one or more other antiretroviral drugs.  
   
   
       15 . A composition according to  claim 14  wherein the one or more other antiretroviral drugs are selected from the group consisting of NRTIs, NNRTIs, protease inhibitors, entry inhibitors, integrase inhibitors, TAT inhibitors, maturation inhibitors, immunomodulating agents, antifungal agents and antibacterial agents.  
   
   
       16 . A method of treating HIV infection in a human which comprises administering a therapeutically effective amount of a compound according to  claim 1  or a pharmaceutically acceptable salt thereof.